Cantor Fitzgerald L. P. Purchases Shares of 17,000 Amedisys, Inc. (NASDAQ:AMED)

Cantor Fitzgerald L. P. purchased a new stake in Amedisys, Inc. (NASDAQ:AMED - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 17,000 shares of the health services provider's stock, valued at approximately $1,543,000. Cantor Fitzgerald L. P. owned approximately 0.05% of Amedisys at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Blue Trust Inc. boosted its position in shares of Amedisys by 55.1% during the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider's stock worth $34,000 after acquiring an additional 124 shares in the last quarter. HBW Advisory Services LLC bought a new stake in Amedisys during the fourth quarter worth $38,000. Versant Capital Management Inc boosted its holdings in shares of Amedisys by 68.5% in the 4th quarter. Versant Capital Management Inc now owns 450 shares of the health services provider's stock valued at $41,000 after purchasing an additional 183 shares in the last quarter. Johnson Financial Group Inc. bought a new position in shares of Amedisys in the 4th quarter valued at $55,000. Finally, Vestcor Inc acquired a new position in shares of Amedisys during the 4th quarter worth $73,000. 94.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Stephens reaffirmed an "equal weight" rating and issued a $101.00 price objective on shares of Amedisys in a research note on Tuesday, March 4th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $100.00 target price on shares of Amedisys in a research note on Wednesday, April 16th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $100.75.

Amedisys Trading Down 0.9 %

AMED traded down $0.90 during trading on Thursday, reaching $95.24. 370,953 shares of the company's stock were exchanged, compared to its average volume of 415,546. The firm has a fifty day moving average price of $92.91 and a two-hundred day moving average price of $91.74. The stock has a market capitalization of $3.13 billion, a PE ratio of 37.79, a price-to-earnings-growth ratio of 1.78 and a beta of 0.96. Amedisys, Inc. has a one year low of $82.15 and a one year high of $98.95. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05.

Amedisys (NASDAQ:AMED - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.12. The business had revenue of $594.78 million during the quarter, compared to analyst estimates of $597.43 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. Amedisys's revenue for the quarter was up 4.1% compared to the same quarter last year. During the same period last year, the company earned $1.03 EPS. As a group, equities research analysts forecast that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.